Supporting Sinus Wellness and Immune Health with Intranasal Light Therapy

Intranasal Light Therapy for Sinus and Immune Health

Of all the ways to deliver photobiomodulation, intranasal application is among the most anatomically strategic. The nasal cavity is richly vascularised, sits adjacent to key lymphatic and neural tissue, and provides direct optical access to areas that panels and masks cannot reach from the outside.

Why the Nasal Route Matters

The nasal mucosa contains a dense network of blood vessels close to the surface — so close that light delivered intranasally can directly irradiate circulating blood as it passes through the nasal capillary bed. This is the same principle behind intravenous laser blood irradiation used in clinical settings, but delivered non-invasively.

Beyond blood irradiation, the nasal cavity is anatomically adjacent to:

• The olfactory epithelium — which has direct projections into the brain, offering a potential pathway for transcranial photobiomodulation effects without penetrating the skull
• The paranasal sinuses — including the maxillary, ethmoid, and sphenoid sinuses, all of which can be affected by chronic inflammation
• The lymphatic tissue of Waldeyer's ring — tonsils and adenoids that form part of the upper respiratory immune defense
• The trigeminal nerve — the largest cranial nerve, whose branches run through nasal tissue and connect to broad areas of the face and brain

Wavelengths Used in Intranasal PBM

Two wavelengths dominate intranasal photobiomodulation research:

650nm (red): Primarily targets superficial nasal mucosal tissue. Effective for reducing local inflammation, improving mucosal immune function, and modulating mast cell activity in allergic rhinitis. The 650nm range is also the primary wavelength for blood irradiation effects as light penetrates the superficial capillary bed.

810nm (near-infrared): Penetrates more deeply, reaching nasal bone, adjacent sinus cavities, and potentially the olfactory nerve. At this wavelength, transcranial effects become plausible — 810nm has the strongest evidence base for neurological photobiomodulation in transcranial PBM research.

The MitoBOOST delivers both wavelengths, providing coverage across both the mucosal/immune and the deeper neural pathways.

Sinus Inflammation and Chronic Sinusitis

Chronic rhinosinusitis affects approximately 12% of adults and is characterised by persistent mucosal inflammation, impaired mucociliary clearance, and often secondary bacterial or fungal colonisation. Standard treatments — antibiotics, corticosteroids, surgery — address symptoms but rarely resolve the underlying inflammatory dysregulation.

Photobiomodulation addresses sinus inflammation through several mechanisms:

• NF-κB suppression: The master inflammatory signalling pathway is downregulated by PBM at 630–850nm, reducing production of IL-1β, IL-6, and TNF-α — the same cytokines driving chronic sinusitis
• Mast cell modulation: PBM reduces mast cell degranulation, relevant for allergic rhinitis where mast cell activation drives the inflammatory cascade
• Nitric oxide release: Improved vasodilation and mucosal blood flow supports tissue oxygenation and immune cell trafficking
• Antimicrobial effects: Some evidence suggests PBM has direct effects on biofilm-forming bacteria common in chronic sinusitis, though this is less studied than the anti-inflammatory pathway

Immune Modulation and Systemic Effects

One of the more remarkable aspects of intranasal PBM is its potential for systemic immune effects via blood irradiation. As blood circulates through the nasal capillary bed, photons at 650nm and 810nm can influence circulating immune cells — particularly lymphocytes, neutrophils, and natural killer cells.

Research on intravenous laser blood irradiation (the clinical analogue) has documented increases in lymphocyte activity, improvements in neutrophil phagocytic capacity, and normalisation of inflammatory cytokine profiles. Intranasal delivery achieves similar — if less intensive — blood irradiation non-invasively.

For immune support during illness, this systemic effect is particularly relevant. Studies using intranasal PBM during respiratory infections have shown reductions in symptom duration and severity, likely through enhanced innate immune response and reduced inflammatory tissue damage.

Respiratory Illness Applications

Interest in intranasal PBM for respiratory illness increased significantly following research into its potential role in COVID-19 recovery, particularly for post-viral symptoms including anosmia (loss of smell) and persistent nasal inflammation. While large-scale RCT data is still emerging, case series and small trials have shown promising results for:

• Reduction in nasal congestion and inflammation during acute respiratory illness
• Accelerated recovery of olfactory function post-viral infection
• Reduction in post-COVID nasal symptoms in small observational studies

These applications align with the established mechanisms — the olfactory epithelium is directly accessible intranasally, and PBM's well-documented neuroprotective and anti-inflammatory effects are directly relevant to post-viral neural damage.

Protocol Recommendations

For general immune support and sinus health maintenance:

• Frequency: Daily or 5x/week during periods of immune challenge; 3x/week for maintenance
• Duration: 20–25 minutes per session (typical for intranasal devices delivering lower irradiance at close range)
• Timing: Morning use supports circadian immune function; evening use is also appropriate
• During active illness: Daily use; do not use if nasal tissue is actively bleeding or severely inflamed

The MitoBOOST is designed for comfortable intranasal use with a soft, ergonomic tip sized for adult nasal anatomy.

Safety Considerations

Intranasal PBM has an excellent safety profile in the clinical literature. No adverse events beyond mild transient warmth have been reported at therapeutic doses. Standard contraindications apply: photosensitising medications, active nasal infections with significant tissue damage, and a history of photosensitivity conditions. Always consult our contraindications page before beginning use.

References

1. Huang YY et al. (2011). Biphasic dose response in low level light therapy — an update. Dose Response, 9(4), 602–618.
2. Cassano P et al. (2016). Review of transcranial photobiomodulation for major depressive disorder. Neurophotonics, 3(3).
3. Salehpour F et al. (2019). Brain photobiomodulation therapy: a narrative review. Molecular Neurobiology, 56(8), 6112–6128.
4. Demidova-Rice TN et al. (2007). Acute and impaired wound healing: pathophysiology and current methods for drug delivery. Advances in Skin & Wound Care, 25(7), 304–314.
5. Ailioaie LM & Litscher G. (2021). Photobiomodulation and sports: results of a narrative review. Life, 11(12), 1339.